The Innovation Agency and our fellow AHSNs are offering support to organisations responding to the NHS MedTech Funding Mandate policy.
The policy aims to accelerate the uptake of selected innovative medical devices, diagnostics and digital products. The guidance for 2021/22 is published here.
In 2021/22 the policy will support devices, diagnostics or digital products that:
- are effective: demonstrated through positive NICE guidance;
- deliver material savings to the NHS: the benefits of the innovation are over £1 million over five years for the population of England;
- are cost-saving in-year: NICE modelling demonstrates a net saving in the first 12 months of implementing the technology;
- are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years.
To minimise burden on the NHS at this time, it was agreed that for the first year of the policy only, technologies must have also been previously supported by the Innovation Technology Payment.
The AAC expects hospitals and commissioning organisations to comply with the policy guidance where appropriate. The Mandate directs the NHS to which MedTech innovations are effective and likely to give savings on investment. The NHS Standard Contract will require both commissioners and providers of NHS-funded services to comply, as relevant, with their obligations under, and any recommendations contained in, the MedTech Funding Mandate.
Once the policy becomes effective in April, the NHS Accelerated Access Collaborative (AAC) team will regularly review NICE guidance on medical technologies and diagnostics to identify medical devices, diagnostics and digital products which have been recommended by NICE and are likely to meet the MedTech Funding Mandate criteria in the following year, and highlight these to providers and commissioners.